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The vitamin D system comprises a group of metabolites, of
which calcitriol or 1,25(OH)2D is the most active form, although
its substrate calcidiol or 25(OH)D is also able to activate the vita-
min D receptor.
In order to have a correct vitamin D supplementation policy, it is
mandatory to understand the regulation and functionality of the
vitamin D system, the definition of “normality” and the objec-
tives to achieve.
Although 25(OH)D activity is lower than 1,25(OH)2D by a factor
of 100, its serum concentration is 1000-times higher, so 25(OH)D
is believed to substantially contribute to the overall vitamin D ef-
fect on target organs.
For several years we have been using a wrong threshold for
25(OH)D “sufficiency” mainly in people older than 50 years.
Nowadays, however, several studies indicate that the most ade-
quate or sufficient 25(OH)D levels in patients under risk of meta-
bolic bone diseases should be 30-40 ng/mL. Thus, considering
the factors involved in vitamin D metabolism, the population at
risk of vitamin D deficiency is extraordinarily high and should be
considered as a public health priority.
In most European countries, fortification of dairy products is for-
bidden and in the USA the FDA (Foods and Drugs Administra-
tion) limited fortification exclusively to milk and cereals. Al-
though food fortification has demonstrated being useful in the
normalization of vitamin D levels, the issue on the adequate
dose is still pending.
To summarize, the best attitude regarding vitamin D supplemen-
tation is to admit that most patients under risk of metabolic bone
disease would need 25(OH)D supplementation. A dose of 800-
1600 UI/day (with an adequate calcium intake), administered ei-
ther daily or periodically would allow to achieve adequate levels
in most patients. 
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Despite the fact that vitamin D is still called and known as a vit-
amin, it actually comprises a group of very closely interrelated
hormonal compounds also related to the other main regulatory
hormone of the mineral metabolism (and, therefore, bone me-
tabolism), the parathormone (PTH). Accordingly, in order to de-
velop a rightful vitamin D supplementation policy, it is mandato-
ry to understand the regulation and functionality of the system,
the definition of “normality”, the objectives to achieve and
whether these objectives are therapeutic or if their aim is to op-
timize the possible effects of other therapeutic agents. 
Vitamin D hormonal system
The vitamin D hormonal system comprises different metabo-
lites derived from the cholecalciferol precursor (vitamin D3),
which is either synthesized in the skin under the influence of
UVB light and temperature, or has a dietary origin. Endoge-
nous vitamin D belongs to the vitamin D3 series, whilst some
vitamin D supplements belong to the vitamin D2 series (plant
origin) (1). The first enzymatic reaction takes place in the liver,
where these metabolites are hydroxylated, thus forming the 25-
hydroxyvitamin D [25(OH)D]. 25(OH)D has a long half-life of
about 3-4 weeks and is the best indicator of vitamin D status in
the body (2, 3). 25(OH)D is the substrate for the 1-α-hydroxy-
lase which catalyzes the synthesis of 1,25-dyhydroxyvitamin D
[1,25(OH)2D] or calcitriol mainly in the kidney, although nowa-
days the existence of this enzyme in many other tissues is well
known (4). Calcitriol, which is actually the most active form of
vitamin D [100-times higher than 25(OH)D] has a very short
half-life, about a few hours.
Calcitriol and other metabolites act in their target tissues
through its receptor, vitamin D receptor (VDR), which is a
member of the steroid receptor superfamily. The VDR is a cal-
citriol-activated transcription factor that interacts with several
coregulators, thus altering the transcription rate of the target
genes. However, some non-genomic actions have been de-
scribed for the vitamin D, and there is still controversy about
whether these actions are carried out through the VDR or
through a specific membrane receptor (4).
The activity of 1-α-hydroxylase in the kidney is the main mech-
anism of the calcitriol synthesis regulation. This enzyme is syn-
thesized along the whole human nephron (5) and the reaction
is normally not substrate-dependent, i.e. it does not depend on
the plasma levels of 25(OH)D, although it is stimulated by the
parathyroid hormone (PTH) and inhibited by phosphate. 
Traditionally, the main action of vitamin D has been described
thus: “to increase serum calcium and phosphate levels for a
correct bone mineralization in order to avoid rickets in children
and osteomalacia in adults”. Nevertheless, once these severe
conditions have been solved, epidemiologic studies have high-
lighted the link between vitamin D deficiency and other preva-
lent diseases such as osteoporosis, common cancers and au-
toimmune diseases, leading, in the last five years, to the ne-
cessity of re-defining the normal levels of vitamin D in normal
population as well as in patients affected by these diseases. 
vitamin D actions depend on: the serum levels of vitamin D
metabolites, the VDR density (upregulated by vitamin D), and
the qualitative aspects of the VDR, as observed in several
studies related to bone mineral density (6-12), intestinal calci-
um absorption (13-15) and bone response to different thera-
peutic agents according to VDR gene polymorphisms (16-18).
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Importance of 25(OH)D
In the past, it was assumed that the 25(OH)D concentration was
largely irrelevant because of the biologically active metabolite,
1,25(OH)2D or calcitriol, which is synthesized in the kidney and
it is more potent by a factor of more than 100. On the other
hand, 25(OH)D is able to activate the VDR, although with lower
affinity. Since the 25(OH)D concentration is higher than the
1,25(OH)2D concentration – by a factor of more than 1000 –,
many investigators believe that 25(OH)D contributes substan-
tially to the overall vitamin D effect on target organs. Besides
this fact, it also bears consideration that many tissues, for in-
stance osteoclasts and vascular smooth muscle cells, express
1-α-hydroxylase activity. Although such locally produced
1,25(OH)2D does not make a major contribution to circulating
1,25(OH)2D (as reflected by the low 1,25(OH)2D concentrations
in anephric individuals), the local 1,25(OH)2D concentrations in
such tissues may be another matter and may actually make a
significant contribution to hypothetical local paracrine actions
(e.g. in bone) (4). Under normal circumstances, the activity of
the renal 1-α-hydroxylase is strictly regulated by product inhibi-
tion, and the synthesis of 1,25(OH)2D is not substrate-depen-
dent. In contrast, in some pathological states including chronic
kidney disease, renal 1-α-hydroxylase does become substrate-
dependent. This implies that if the concentration of 25(OH)D3 is
raised, the production of 1,25(OH)2D3 increases (19). 
Thus, the real importance of the 25(OH)D levels in patients
whose renal function is worsened with age is conditioned by
four different aspects (20): 
1. Since 1-α-hydroxylase becomes substrate-dependent,
25(OH)D levels influence calcitriol levels.
2. Both 25(OH)D and calcitriol can bind VDR. Calcitriol affinity
is higher by a factor of 2400, but 25(OH)D concentration is
1000-times higher.
3. Some vitamin D actions, like intestinal calcium absorption,
are mostly VDR independent (1:8 Potency Ratio).
4. 25(OH)D levels can play an important role as a paracrine lo-
cal factor due to the existence of the extra-renal 1-α-hydrox-
ylase activity.
There has been an erroneous concept regarding which concen-
trations of 25(OH)D are optimal. The distribution of values fol-
lows a Gaussian curve and the mean value depends on age.
The age-dependent decline in 25(OH)D3 is not desirable, how-
ever because, for the reasons given above, it is associated with
a diminished intestinal calcium absorption, an increased resorp-
tion of skeletal mineral and increased PTH concentrations. 
Observations in general population indicate that PTH concen-
trations are lower, the intestinal calcium absorption rate is high-
er and less mineral is released from the skeleton when
25(OH)D concentrations are in the range of 20 ng/mL (50
nmol/L) or higher. Moreover, intestinal absorption curve reach-
es plateau when 25(OH)D levels are around 30-40 ng/mL (21). 
When it comes to diagnosing a vitamin D deficiency and pin-
pointing the exact level at which it occurs, there is no definitive
consensus. Traditionally, vitamin D values below 5-7 ng/mL in-
duce osteomalacia; values lower than 10-12 ng/mL lead to
secondary hyperparathyroidism and osteoporosis; and levels
above 18-20 ng/mL could be considered normal (22). These
values, which may be adjusted to reflect what happens to
young people, have proven to be insufficient for an adequate
calcium and bone metabolism homeostasis in elderly people.
These observations have recently led to an “upward” revision
of what is supposed to be the optimal serum concentration of
25(OH)D.
Several factors determine vitamin D levels: those affecting the
skin synthesis of vitamin D through ultraviolet radiation and nu-
trition, and those which can modify the vitamin D metabolism
(2). Moreover, vitamin D measurement methods have a great
variability intra- and inter-laboratories, masking the effect of the
aforementioned factors, and thus making the comparison be-
tween different populations difficult (23, 24).
It has been recently proposed that: 1) levels > 40 ng/mL (>
100 nmol/L) are desirable; 2) hypovitaminosis D occurs when
the concentration is between 20 and 40 ng/mL (50-100
nmol/L); 3) there is a vitamin D insufficiency when the concen-
tration is between 10-20 ng/mL (25-50 nmol/L) and 4), there is
vitamin D deficiency when values are lower than 10 ng/mL (<
25 nmol/L) (25).
The prevalence of vitamin D deficiency depends on the cut-off
point used, as well as the type of population studied. There-
fore, a vitamin D deficiency was found in almost all chronic
geriatric patients (26) and in 57% of the American acute symp-
tomatic patients (27). This prevalence was 36% of men and
47% of women in European elderly population. Surprisingly,
the most southerly countries showed the lowest levels (28),
and in women with post-menopausal osteoporosis, the defi-
ciency prevalence was 0% in Singapore, 3.5% in the USA and
slightly above 10% in France and Spain (29). Furthermore, a
95% of centenary patients had undetectable (< 5 ng/mL) levels
of 25(OH)D (30).
In our self-ambulating non-selected population the prevalence
of 25(OH)D values < 18 ng/mL was 50% in the summer and
72% in the winter, in those between 55-65. These percentages
increased to 58% and 80% in the summer and the winter re-
spectively when people older than 65 were selected (19). On
the other hand, no cases of hyperparathyroidism were observed
in those people whose levels of 25(OH)D were 30 ng/mL (75
nmoles/L) or higher; only a 7% of the population presented lev-
els of 25(OH)D above this value during the whole year.
Which 25-D-hydroxyvitamin serum values should be the
goal to achieve in adult populations?
The previous considerations indicate that the most adequate
or sufficient 25(OH)D levels in our population under risk of
metabolic bone diseases should be 30-40 ng/mL. These levels
are considered clinically adequate and safe for the manage-
ment of patients under risk of developing metabolic bone dis-
eases and/or secondary hyperparathyroidism (31) and they
are located where intestinal calcium absorption is optimized,
PTH levels are maintained within the normal range, and a
higher bone mineral density and lower risk for peripheral frac-
tures with respect to a vitamin D deficient population were ob-
served (Figure 1). 
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Figure 1 - The picture shows a schematic representation in which can
be seen how while 25(OH)D levels increase, calcium absorption also
increases, and PTH levels and the risk of fractures decrease. 30 ng/mL
of 25(OH)D are necessary to achieve the maximum calcium absorption,
the lowest PTH levels and a low risk of osteoporotic fractures. 
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In osteoporotic patients, considering different criteria (PTH lev-
els, calcium absorption, bone mass, falls and reduced risk for
non-vertebral fractures) and based on the results from con-
trolled clinical trials, an experts’ committee proposes a mini-
mum level of 25(OH)D between 20-32 ng/mL, and a desirable
objective between 28-32 ng/mL (32). In order to achieve these
levels, a dairy dose of vitamin D3 of 800-1600 UI, with an ade-
quate calcium intake, was necessary.
Who should receive vitamin D supplementation?
The factors influencing 25(OH)D concentrations can be
grouped into three broad categories (2):
(i) First, factors which affect the cutaneous synthesis of vita-
min D under the influence of UVB radiation. These factors
comprise age, melanin concentration in the skin and condi-
tions modulating the intensity of sun exposure, such as
season of the year, latitude, altitude and type of clothing.
(ii) Second, nutritional factors (although, under normal circum-
stances, the dietary supply of vitamin D makes only a minor
contribution to the overall vitamin D status). Dietary
sources of vitamin D include raw and cooked fish and dairy
products, as well as polyvitamin preparations containing vit-
amin D or (in the USA) food items enriched with vitamin D,
such as milk products and vegetable fats (2). 
(iii) Third, the 25(OH)D concentration is modulated by factors
which affect the metabolism of vitamin D. Examples in-
clude substances which diminish intestinal absorption or
interrupt the intestinal resorption of vitamin D metabolites
(enteric recirculation) as well as drugs which alter the ac-
tivity of the hepatic CYP enzymes and accelerate the ca-
tabolism of 25(OH)D into inactive vitamin D metabolites in
the liver.
Considering the factors involved in vitamin D metabolism and
the epidemiologic data mentioned above, the population at risk
of vitamin D deficiency is extraordinarily high and could even
be considered a Public Health problem. Vitamin D supplemen-
tation, however, is still not recommended under the age of 65
(33) in some prestigious guidelines for clinical practice on Os-
teoporosis.
It is important to highlight the relevance of the repletion of
25(OH)D deposits, even in chronic kidney disease patients, in
which a partial or total deficit of 1-α-hydroxylase activity exists.
In fact, the correlation between PTH and 25(OH)D levels is
maintained in patients in haemodialysis as well as in those who
have received a kidney transplant (19, 20, 34-37). 
Furthermore, migration movements that have led people from
Southern countries to Northern countries, with darker skin and
with dietetic and clothing habits that result in a lessened sun
exposure, may imply a higher risk for such populations (38,
39).
Would food fortification be enough?
Sun exposure, in order to stimulate vitamin D synthesis in the
skin, sets out difficulties due to the lower capacity of synthesis
elderly people possess, the negative effects on senile skin in-
juries and even due to the fact that melanin induction blocks
UV light transition. Therefore, the observation that in Mediter-
ranean countries vitamin D levels are lower than those of
Nordic countries would be determined by the natural protection
a darker skin provides to solar irradiation. Thus, dietetic vitamin
D sources play a predominant role. 
Fortification of several foods was set out several years ago
when rickets and osteomalacia were frequent. Milk, bread, hot
dogs, refreshments and even beer were enriched with vitamin
D (40). However, the outbreak of vitamin D intoxication in Eu-
rope and the strict regulations by the FDA (Food and Drug Ad-
ministration) limited fortification exclusively to milk and cereals
(41). In most European countries, fortification of dairy products
is forbidden and the prevalence of lactose intolerance, milk al-
lergies and the risk of intoxication in people whose diet is
based on milk is not suitable for preventing vitamin D insuffi-
ciency. In addition, the vitamin D contents of milk is highly vari-
able (42). Although food fortification, even in non-diary food,
has demonstrated being useful in the normalization of vitamin
D levels (40), the issue on the proper dosage is still pending.
Furthermore, fortified products have an added, higher, non-jus-
tificable cost than non-fortified food. 
Which is the best metabolite and the adequate dosage for
vitamin D supplementation?
As Dr. Heaney emphasized: “Vitamin D is inexpensive to man-
ufacture and to administer. (Maybe that is part of the reason for
the problem). By contrast, the cost of vitamin D deficiency,
while yet to be fully reckoned, may well be massive” (43). 
Vitamin D metabolites availability is limited to vitamin D2 (ergo-
calciferol), vitamin D3 (cholecalciferol) and 25-hydroxyvitamin
D (25-hydroxycholecalciferol or calcidiol). Paradoxically, calcid-
iol, the most effective and fastest way to normalize vitamin D
levels, is not manufactured in the USA any longer (43). The
most common one is vitamin D3, although the specific presen-
tations (without calcium) are also limited. In Spain there’s only
one commercial cholecalciferol solution available (drops) and a
commercial calcidiol trademark (drops, blisters) but there are
no parentheral solutions, which are available in other countries
and that allow for more sporadic charging dosages while solv-
ing malabsorption problems.
Cholecalciferol effectiveness is higher than that of vitamin D2
(44), and most of the published studies have been performed us-
ing vitamin D3 alone or combined with calcium supplements (32,
45). Furthermore, taking calcidiol weekly or every 3 weeks has
proven to be efficient in achieving an adequate vitamin D reple-
tion (46).
Regarding the recommended dosages, the official recommen-
dations in USA and Canada are 400 UI and 600 UI daily for
people younger and older than 70, respectively (47). In Eu-
rope, 400 UI are maintained for elderly people (48) as well as
the FDA recommendations (49). These dosages have clearly
proven to be insufficient, and clinical evidences increase these
dosages to 800-1600 UI, daily (32). 
It is important to highlight that in recent studies of American
women under osteoporosis treatment or prevention, of which
60% of them were receiving vitamin D supplements, the preva-
lence of women with levels of 25(OH)D < 30 ng/mL was 63% in
those having less than 400 UI and 45% in those having 400 UI
or more (50). The independent risk factors related to inade-
quate levels of vitamin D in this population were: age over 80,
no Caucasian, BMI >30, medication that may interfere with the
vitamin D metabolism, no sport practice, vitamin D supplemen-
tation under 400 UI, low cultural level, and no explanation by
the physician about the importance of vitamin D.
Up to date, no vitamin D toxicity due to an excess of sun ex-
posure has been described, only toxicity by hypervitaminosis
D has been associated to daily dietary doses over 10,000 UI
(250 μg) (51). No toxicity was either observed when 4,000 UI
(100 μg) or 50,000 UI (1,250 μg) were daily or weekly admin-
istered, respectively (52, 53). Moreover, in a double blind, ran-
domized and controlled with placebo assay (n=2686), 100,000
UI (2,500 μg) of Cholecalciferol every four months were safe
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and efficient in decreasing the incidence of osteoporotic frac-
tures (54).
To summarize, the most correct attitude regarding vitamin D sup-
plementation, is to admit that most of the patients under risk of
metabolic bone disease will be in need of such supplementation.
25(OH)D and PTH level quantifications will provide us with valu-
able information about their mineral homeostasis. An adequate
dose, 800-1600 UI/day, administered either daily or periodically,
would allow achieving levels of sufficiency in most patients. In
cases of malabsorption or in cases of medical treatments which
activate vitamin D degradation (phenitoin), larger doses or even
parentheral administration may be necessary.
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